At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Bortezomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Study of Bortezomib in Combination With Melphalan and Prednisone for Patients With Previously Untreated Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Bortezomib, Melphalan, and 1 other intervention for Multiple Myeloma. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the efficacy of bortezomib in combination with melphalan and prednisone to achieve complete responses for patients with previously untreated multiple myeloma compared to an historical control group. This trial will also evaluate the safety and toxicity of this regimen as well as evaluate the duration of response of this regimen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2004
Primary CompletionFeb 2008
First PostedAug 2008
TodayJul 2026
First PostedAug 14, 2008
Enrollment StartJul 1, 2004
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 17.9 years ago
Interventions
Bortezomibdrug
Melphalandrug
Prednisonedrug